Vedanta Biosciences, Inc.

A New Class of Drugs to Treat Gastrointestinal Diseases Through Microbiome Modulation

We are pioneering rational design of drugs for the treatment of serious gastrointestinal diseases using defined consortia of bacteria that are essential dwellers of the gut ecosystem.

Get to Know Us View Video

What Makes Us Unique

Where Medicine Meets Ecology

icon

Transformative Science

We have pioneered the discovery of commensal gut bacteria involved in immune regulation and immune potentiation.

View Publications View Scientific Advisory Board
icon

Defined Bacterial Consortia Therapeutics

Our field-leading product engine enables identification of bacteria with drug-like properties and their assembly into rationally-designed consortia for optimal therapeutic activity. We are the first to achieve commercial-scale CGMP production of drug candidates based on defined bacterial consortia – the future of microbiome therapies.

View Product Engine
icon

Foundational Intellectual Property

Our issued patents broadly cover bacterial consortia drugs containing Clostridium organisms, one of the most abundant groups of bacteria in the gut.

View Intellectual Property (IP)

In The News

View the latest of Vedanta in recent publications

logo-the-economist
logo-endpoints-news
logo-nature-biopharma-dealmakers
logo-the-boston-globe
logo-the-lancet-microbe
logo-cell-host-and-microbe
logo-nature

Join Our Team

We are working to provide doctors and patients with an entirely new option to treat gastrointestinal diseases: medicines based on live bacterial consortia that can colonize the human intestine. We believe developing this new type of medicines takes careful science and the best brains in the fields of microbial ecology, immunology, bioinformatics, process development, and manufacturing, among others. If you find this as exciting as we do, we want to hear from you!

Get to Know Us